All < Article List - KBR

Government to review proposal to postpone med student increase for 1 year: vice minister

The government said Monday that it would conduct an internal review of the Korean Medical Association (KMA)'s emergency committee's proposal to re-discuss increasing the number of medical students after a one-year moratorium.The government also said that although the enrollment quota has been alloca
Policy Kwak Sung-sun 2024.04.08 15:24
[Photo News] UK Health Security Agency Chief Executive visits Seegene headquarters in Seoul

Seegene, a Korean in vitro diagnostics company, recently hosted Jenny Harries, Chief Executive of the UK Health Security Agency (UKHSA), at its headquarters in Songpa-gu, Seoul.The visit, which took place on March 27, served as a platform for both parties to discuss innovative strategies to create a
Device/ICT Lee Han-soo 2024.04.08 14:30
Lunit AI software proves early breast cancer detection, reduced workload for radiologists

Lunit said it published a study showing that using Lunit Insight MMG, its AI image analysis solution for mammography, can increase the likelihood of early breast cancer diagnosis and significantly reduce the workload of physicians.The study, conducted in collaboration with researchers from various u
Device/ICT Lee Han-soo 2024.04.08 14:06
Pinotbio releases preclinical results of new drug and linker at AACR 2024

Pinotbio is increasing its competitiveness on the global stage by emphasizing effectiveness and safety by combining the “PBX-7 Series” and “sequential cleavage linker.”Pinotbio, an ADC platform company, said Monday that it unveiled preclinical results of its ADC platform at the American Association
Bio Korea Biomedical Review 2024.04.08 14:00
'Japanese model of med school enrollment, regional quota system might be a lesson for Korea'

As the government and the medical community debate the increase in medical school enrollment quota, it has been suggested that Korea should learn from Japan, which increased medical school students and operates a regional quota system to solve the problem of regional medical disparities ahead of Kor
Policy Kim Eun-young 2024.04.08 13:38
Korean patients seek WHO intervention amid healthcare standoff

As the healthcare void continues due to a standoff between the government and the medical community over the increasing number of medical students, a patient group said it would ask the World Health Organization (WHO) to intervene in the ongoing medical crisis in Korea.The Korea Severe Disease Assoc
People Kim Ju-yeon 2024.04.08 13:19
Korean and foreign experts jointly tackle threats of pancreatic and biliary disease

Amid a growing consensus that domestic and international medical practitioners should collaborate to find solutions to the growing risk of pancreatic and biliary tract diseases, some experts stressed the need for active state support for research investment to develop treatments and diagnostics.The
Hospital Kim Chan-hyuk 2024.04.08 11:26
EuBiologics opens new office in Boston's Cambridge Innovation Center to accelerate global vaccine development

EuBiologics, a Korean vaccine maker targeting the global public health market, said it opened a new office at the Cambridge Innovation Center (CIC) in Boston, one of the largest biotech clusters in the world.EuBiologics' new office opening comes after their selection by KHIDI (Korea Health Industry
Pharma Lee Han-soo 2024.04.08 10:56
Severance Hospital's study validates efficacy of stereotactic ablative radiotherapy for limited metastatic cancer cases

A team at Severance Hospital found that stereotactic ablative radiotherapy (SABR) was effective in treating patients with limited metastatic liver cancer.Limited metastatic cancer is defined by the early stage of cancer spread, where metastasis is confined to five or fewer organs.This condition nece
Hospital Lee Han-soo 2024.04.05 17:06
Why are there radiotherapy limits for neuroendocrine tumors if there aren't any for thyroid cancer?

As the benefits of treating cancer with "radioactive" substances that emit radiation, such as alpha, beta, gamma, X-ray, and positron rays, have become established, radiopharmaceutical cancer therapy, which has been introduced for thyroid cancer, pediatric neuroblastoma, and neuroendocrine tumors, i
Hospital Kim Kyoung-Won 2024.04.05 16:39
Hanmi Science appoints youngest son as new Co-CEO

In a move signaling a potential resolution to ongoing family disputes, Hanmi Science, the holding company of Hanmi Pharm, announced the appointment of Lim Jong-hoon as co-CEO alongside the current chairperson, Song Young-sook.The decision came during a board meeting held at Hanmi headquarters in Son
Pharma Lee Han-soo 2024.04.05 15:52
Celltrion partners with the Crohn's & Colitis Foundation to enhance IBD awareness in US

Celltrion has embarked on a partnership with the Crohn's & Colitis Foundation (CCF), the largest patient advocacy group for inflammatory bowel disease (IBD) in the U.S., aiming to boost awareness and improve perceptions of IBD, a chronic inflammatory condition of the gastrointestinal tract.The CCF,
Bio Lee Han-soo 2024.04.05 15:09
BR Pharm to present study on HP VITARAN at APS 2024

BR Pharm, a regenerative medicine company, said it would present "Minimizing Procedural Pain and Maintaining Effectiveness" related to HP VITARAN, a skin booster using PN (Polynucleotide Sodium), at APS (AESTHETIC PLASTIC SURGERY) 2024, which will be held at the Grand InterContinental Seoul Parnas S
Pharma Park Gi-taek 2024.04.05 15:07
CG Bio premieres ‘EGF Skin Booster’ at AMWC 2024

CG Bio, a Korean generative medicine developer, said Friday that it participated in the Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2024 in Monaco from March 27 to 29, showcasing its aesthetic total solution products.AMWC is the world's largest plastic surgery and aesthetic clinic congress
Bio Yang Hyeon-su 2024.04.05 15:04
Novartis' rare disease drug Ilaris passes health insurance review panel

Novartis' rare disease treatment Ilaris (canakinumab) has crossed the threshold of the Health Insurance Review and Assessment Service (HIRA)'s Pharmaceutical Reimbursement Evaluation Committee (PREC), which reexamined its “conditional” approval application.At the same meeting, the panel also recogni
Policy Kim Yun-mi 2024.04.05 14:23
Samsung Bioepis initiates global phase 3 study for Keytruda biosimilar

Samsung Bioepis said it has commenced global phase 3 clinical trials for its biosimilar, SB27, a biosimilar referencing Keytruda, a blockbuster cancer treatment developed by MSD.SB27 marks the company's eleventh biosimilar pipeline, illustrating its ongoing commitment to expanding its portfolio in t
Bio Lee Han-soo 2024.04.05 14:07
Bayer's high-dose Eylea lands in Korea to keep retinal disease market share

Eylea Injection 8 mg (aflibercept), which sharply increased the dose from the existing Eylea Injection 2 mg,, has won approval in Korea, drawing attention to whether it will be able to defend its leading position in the retinal disease market from Roche's Vabysmo (faricimab) and Eylea biosimilars.On
Pharma Kim Chan-hyuk 2024.04.05 13:58
Now that cancer treatment is over, is it okay to drink?

After undergoing surgery, chemotherapy, or radiation, many cancer patients adhere strictly to their doctors' advice to abstain from alcohol. However, once their treatment concludes, some may question whether it's acceptable to resume drinking. Is this truly advisable?"In the past, there existed the
Hospital Kim Kyoung-Won 2024.04.05 09:55
Antitrust watchdog FTC probes Novo Nordisk Korea over needle supply cessation

The Fair Trade Commission (FTC) is reportedly looking into Novo Nordisk Korea over allegations of monopolistic practices related to the cessation of its needle supply, NovoFine Plus pen needle.On Thursday, Joongang Ilbo, a Korean daily newspaper, first reported that the FTC's Seoul office dispatched
Pharma Lee Han-soo 2024.04.04 17:10
GC Cell recruits NeoImmuneTech’s former global strategy head as CDO

GC Cell, a contract development and manufacturing organization (CDMO) for cell and gene therapies, said Thursday that it has ushered in Kang Jin-hee, a clinical development and global regulatory expert, as its chief development officer to strengthen its R&D capabilities.According to GC Cell, the new
Pharma Kim Chan-hyuk 2024.04.04 16:45